Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Releases New Drug GMPs; Domestic Consolidation Expected To Accelerate

This article was originally published in The Pink Sheet Daily

Executive Summary

Multinational pharmas operating in China will need to review their manufacturing practices comprehensively to ensure full compliance because China's GMP 2010 standards contain numerous unique requirements that are different from the U.S. and ICH/EU GMPs.

You may also be interested in...



Pharmatech Associates Bikash Chatterjee And Chat Kwan On China's Shift To A Global Standard With New GMP Guidelines: An Interview With PharmAsia News

Headquartered in the San Francisco Bay Area, Pharmatech Associates provides business consulting services in the pharmaceutical, biotech and medical device manufacturing sectors. The company recently held two training programs on the new Chinese Good Manufacturing Practice guidelines in Shanghai. During its Dec. 11 training program, Bikash Chatterjee, the company's president and Chat Kwan, Pharmatech's China president, sat down with PharmAsia News' Shanghai bureau to talk about how the new Chinese GMP guidelines will affect the industry in China and abroad.

China Releases Strictest Ever GMP Draft Guidelines; Laxer Standards Urged For Local Companies

SHANGHAI - China's State FDA recently published a new draft version of Good Manufacturing Practice guidelines for pharmaceuticals on its website for public comment

China Implements New Quality System To Strengthen Drug Safety; Puts Legal Onus On Drug Quality Attorneys

SHANGHAI - China's State FDA launched a new quality system April 10 that requires companies to assign responsibility for drug manufacturing to a drug quality administrator. The move builds accountability into drug manufacturers' systems

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel